4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy

CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T-Cell Lymphomas

(2012) Matthew W. Anderson et al.   AMERICAN JOURNAL OF PATHOLOGY

Expression of CD137 on Hodgkin and Reed-Sternberg Cells Inhibits T-cell Activation by Eliminating CD137 Ligand Expression

(2012) W. T. Ho et al.   CANCER RESEARCH

Oncolytic Virus and Anti-4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established Cancer

(2012) L. B. John et al.   CANCER RESEARCH

Immunotherapy of Cancer with 4-1BB

(2012) D. S. Vinay et al.   MOLECULAR CANCER THERAPEUTICS

Agonist Anti-CD137 mAb Act on Tumor Endothelial Cells to Enhance Recruitment of Activated T Lymphocytes

(2011) A. Palazon et al.   CANCER RESEARCH

Costimulation Through the CD137/4-1BB Pathway Protects Human Melanoma Tumor-infiltrating Lymphocytes From Activation-induced Cell Death and Enhances Antitumor Effector Function

(2011) Jessica Ann Hernandez-Chacon et al.   JOURNAL OF IMMUNOTHERAPY

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Peripheral 4-1BB Signaling Negatively Regulates NK Cell Development through IFN- 

(2010) B. K. Choi et al.   JOURNAL OF IMMUNOLOGY

Mice deficient for CD137 ligand are predisposed to develop germinal center-derived B-cell lymphoma

(2009) S. Middendorp et al.   BLOOD

TNF superfamily: Costimulation and clinical applications

(2009) Dass S. Vinay et al.   CELL BIOLOGY INTERNATIONAL

The role of positive costimulatory molecules in transplantation and tolerance

(2009) Avinash Agarwal et al.   Current Opinion in Organ Transplantation

In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb

(2009) Oihana Murillo et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

4-1BB and CD28 Signaling Plays a Synergistic Role in Redirecting Umbilical Cord Blood T Cells Against B-Cell Malignancies

(2009) Syam Tammana et al.   HUMAN GENE THERAPY

Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy

(2009) Y. H. Kim et al.   MOLECULAR CANCER THERAPEUTICS

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

(2009) C. Carpenito et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD137 enhances cytotoxicity of CD3+CD56+ cells and their capacities to induce CD4+ Th1 responses

(2008) Bi-qing Zhu et al.   BIOMEDICINE & PHARMACOTHERAPY

Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice

(2008) Seong-A Ju et al.   INTERNATIONAL JOURNAL OF CANCER

Mesothelin targeted cancer immunotherapy

(2007) Raffit Hassan et al.   EUROPEAN JOURNAL OF CANCER